Advanced Oncotherapy names Nicolas Serandour CEO
Mr. Serandour joined Advanced Oncotherapy in September 2014 as Chief Financial Officer.
He has over 15 years of experience in the investment banking industry, having worked at JP Morgan, Lehman Brothers and Lazard, where he was responsible for coordinating the European Healthcare sector coverage.
Mr. Serandour is graduated from ESSEC with a background in finance and accounting. He received a post-degree master in risk management (DESS 203) at Universite Paris Dauphine.
Michael Sinclair, currently Chief Executive Officer and Executive Chairman, will retain his role as Executive Chairman.
Dr. Sinclair qualified in medicine from the Middlesex Hospital, London in 1967 and held a number of appointments at teaching hospitals in London. He became a Registrar in Psychiatry at the Maudsley Hospital and Institute of Psychiatry of London University before entering business in 1971.
Between 1971 and 1977 Dr. Sinclair held senior board positions with Allied Investments Limited, which had operating interests in nursing homes through Nestor Nursing Homes, nursing agencies through the British Nursing Association, deputising services for doctors, medical equipment distribution, the management of hospitals for governments in the Middle East and the operation of a health spa.
In 1979, Dr. Sinclair founded Sinclair Montrose Trust Limited as a private investment vehicle for him and his family. He was chairman and founder of Lifetime Corporation Inc and serves on the Board of Overseers (emeritus) of the Tufts University School of Medicine.
Dr. Sinclair was also the chairman and founder of U.S.- based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP. He is the Chairman of Lightlake Therapeutics Inc. ■
What to read next
LATEST MOVES FROM United Kingdom
- John Lewis Partnership appoints Laura Wade-Gery as director
- 40% of senior executives to leave Reckitt Benckiser
- Oxford Immunotec Global appoints Stefan Linn as COO
- Terra Firma Capital appoints Jerry Patava to board
- Willis Towers Watson announces Michael J. Burwell as CFO
More inside POST